Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07794670
PHASE2
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
Sponsor: NewAmsterdam Pharma
View on ClinicalTrials.gov
Summary
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
Official title: A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)
Key Details
Gender
All
Age Range
55 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2026-09
Completion Date
2029-05
Last Updated
2026-09-28
Healthy Volunteers
No
Conditions
Interventions
DRUG
Obicetrapib 10 mg
once daily 10 mg Obicetrapib tablet
DRUG
Matching placebo tablets
matching placebo tablet
Locations (1)
K2 Medical Research
Nashville, Tennessee, United States